|1.||Qiu, Rongguo: 2 articles (01/2013 - 10/2012)|
|2.||Tang, Li: 2 articles (01/2013 - 10/2012)|
|3.||Lin, Wenlong: 1 article (03/2014)|
|4.||Wang, Xiaojian: 1 article (03/2014)|
|5.||Gu, Meidi: 1 article (03/2014)|
|6.||Cao, Xuetao: 1 article (03/2014)|
|7.||Ouyang, Chuan: 1 article (03/2014)|
|8.||Zhang, Ting: 1 article (03/2014)|
|9.||Xia, Zongping: 1 article (03/2014)|
|10.||Sun, Yan: 1 article (01/2013)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2013 - "Tautomycetin (TMC), originally isolated from Streptomyces griseochromogenes, has been suggested as a potential drug retaining specificity toward colorectal cancer. "
12/01/2006 - "The growth inhibitory effect of tautomycetin was acquired by regulation of Raf-1 activity through inhibition of protein phosphatase type 1 and protein phosphatase type 2A with high preference toward protein phosphatase type 1. Tautomycetin could be a potential drug for colorectal cancer."
12/01/2006 - "The proliferation and anchorage-independent growth of HCT-15, HT-29, and DLD-1 colorectal cancer cells were efficiently inhibited without induction of apoptosis by 150 nmol tautomycetin. "
12/01/2006 - "We have identified the roles of tautomycetin on cellular proliferation and transformation of colorectal cancer cells. "
12/01/2006 - "Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction via the extracellular signal-regulated kinase pathway."
|3.||Dehydration (Water Stress)
|4.||Breast Neoplasms (Breast Cancer)
01/01/2007 - "To date, the list of inhibitors includes okadaic acid (produced by marine dinoflagelates, Prorocentrum sp. and Dinophysis sp.), calyculin A, dragmacidins (isolated from marine sponges), microcystins, nodularins (cyanobacteria, Microcystis sp. and Nodularia sp.), tautomycin, tautomycetin, cytostatins, phospholine, leustroducsins, phoslactomycins, fostriecin (soil bacteria, Streptomyces sp.), and cantharidin (blister beetles, approx 1500 species). "